Europe's Biggest Bet on Itself Just Got a $1.2 Billion Price Tag

That last point is key to Jeito's entire model. The firm isn't trying to build the next Novo Nordisk from scratch. It's financing clinical-stage companies at value inflection points (the moments when data either makes or breaks a drug) and positioning them for acquisition by large pharma companies hungry for new products.

The Report Card So Far

Any investor can raise a big fund with a slick pitch deck. The question is whether the strategy actually works. Jeito's early track record suggests it does.

Two exits stand out. The firm sold EyeBio to Merck & Co. for up to $3 billion and HI-Bio to Biogen for up to $1.8 billion. Both deals closed with an average holding period of just two years. Buy a clinical-stage company, support it through key data readouts, sell it to big pharma. Rinse, repeat.

The current portfolio is stacked with companies at various stages of proving themselves. Azafaros has a lead drug in Phase 3 for rare neurological diseases, backed by a €132 million Series B that Jeito led. Alveus Therapeutics is running a Phase 2 program for a next-generation obesity drug, part of a $197 million Series A. Odyssey Therapeutics raised $213 million in a Series D for autoimmune disease programs. These aren't small bets.

Why This Matters Beyond One Fund

The timing is significant. European biotech has been stuck in an awkward adolescence for years. The continent produces world-class academic research and a steady stream of promising startups, but it lacks the deep pools of growth capital that turn good science into marketed drugs.

Meanwhile, the path of least resistance for ambitious European biotechs has been to list on U.S. exchanges. The talent and the science stay in Europe; the economic upside migrates across the Atlantic.

Jeito's thesis is that this dynamic can be interrupted with the right kind of capital. Not just money, but what the industry calls "patient capital" (funds willing to stick around through the long, expensive slog of clinical development). The firm backs that up with an in-house team of over 30 experts covering drug development, regulatory affairs, intellectual property, manufacturing, and commercial strategy. It's not just a checkbook; it's a support system.

Founder and CEO Dr. Rafaèle Tordjman called the close a "strong signal for the European biopharma ecosystem," pointing to "growing conviction that European companies can drive major therapeutic innovation and significant economic benefits with the appropriate access to financial and strategic resources."

The Bigger Picture

Transatlantic capital flows face increasing policy headwinds. A new coalition of European life sciences VCs, including firms like Forbion and Novo Holdings, has been lobbying for investment-friendly policies to keep more biotech value on the continent. The 2025 funding environment was a mixed bag: fewer but larger deals, creative financing structures for companies without blockbuster data, and a "haves and have-nots" dynamic that rewarded strong clinical results and punished everything else.

Into that landscape, a $1.2 billion European-focused fund sends a clear message. Whether it changes the structural dynamics of European biotech or simply gives one firm a very large war chest remains to be seen.

But for the first time in a while, Europe isn't just complaining about the funding gap. It's writing checks to close it.

Biogen's Bet on a Twisted Piece of Chemistry

Biogen just partnered with Alloy Therapeutics to access a platform that literally reshapes antisense drugs at the molecular level. It's a quiet deal that could unlock targets the company's existing toolkit can't touch.